From Investors Business Daily
Medicine: The FDA has reversed its approval of a widely used cancer drug approved in Europe to treat breast cancer on the grounds it doesn't provide a "sufficient" benefit. Let the terminally ill and their doctors decide.
One of the blessings of blocking the omnibus spending bill was that it included $1 billion for the implementation of ObamaCare.
Yet the first effects are still being felt, the latest being the Food and Drug Administration's revoking of regulatory approval of Avastin to treat late-stage breast cancer.
The reason given by the FDA was that the drug does not provide "a sufficient benefit in slowing disease progression to outweigh the significant risk to patients." What risk? These women are dying.
The drug buys them precious time, and the only risk they face is from an FDA saying "pull the plug."
On the same day the FDA channeled Dr. Kevorkian, its European counterpart, the European Medicines Agency, issued a statement approving Avastin for metastatic breast cancer.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment